The Department of Hepatopancreatobiliary Surgical Oncology is a specialized department with 44 fixed beds, which focuses on various types of liver, gallbladder, bile duct and pancreatic cancer treatment.There are 25 medical staff (7 doctors& 18 nurses),among whom there are 3 chief physicians, 2 deputy chief physicians and 2 attending physicians. All of them are excellent doctors with postdoctoral, doctorate or master degree.

There are more than 400 operations of liver, gallbladder, bile duct and pancreatic tumors carried out every year in the department. At present, laparoscopic hepatocellular carcinoma resection is routinely performed for common hepatic malignant tumors. Hemihepatic resection and caudate lobectomy are performed for giant liver cancer, central liver cancer and especially for caudate lobe tumor. The technology of “in situ liver resection” is used for the treatment of huge liver cancer with severe adhesion to surrounding tissues. For primary liver cancer with a special tumor location or multiple metastatic liver cancer that requires surgery, we have designed a "regional hepatoportal blood flow occlusion " method to remove the tumor, improving the surgical resection rate and the safety. ALPPS (associating liver partition with portal vein ligation for staged hepatectomy) is used for patients with huge liver cancer but insufficient initial residual liver volume. The total resection rate for liver cancer is over 70%.The laparoscopic pancreaticoduodenectomy and distal pancreatectomy or distal pancreatectomy combined with splenectomy is routinely performed for pancreatic cancer. Radical resection, standardized lymph dissection, vascular resection and reconstruction of the superior mesenteric and portal vein can be well performed in the Whipple’s operation. For gallbladder cancer or bile duct cancer, we strictly dissect the lymph nodes around the hepatoduodenal ligament. And radical resection combined with left or right lobe and caudate lobe resection is used for hilar cholangiocarcinoma, which greatly improve the R0 resection rate for hilar cholangiocarcinoma. The enhanced recovery after surgery (ERAS) is the highlight of our department which greatly shorten the postoperative hospital stay.

We hosted several research projects inrecent years, including Natural Science Foundation of Zhejiang Province and other provincial research projects. We also train postgraduate students jointly with Zhejiang Chinese Medical University, Wenzhou Medical University, and Suzhou University.

Last Updated: Mar. 2020